natgillin/translations-raw huggingface dataset:
There are no data in patients with severe hepatic impairment (see sections 4.3, 4.4 and 5.2).
Ni podatkov o zdravilu pri bolnicah s hudo jetrno okvaro (glejte poglavja 4.3, 4.4 in 5.2).
There are no data in patients with severe impairment (creatinine clearance < 30 ml/min).
Podatkov pri bolnicah s hudo okvaro (očistek kreatinina < 30 ml/min) ni.
There are no data in pregnant women.
Podatkov o nosečnicah ni.
There are no data indicating less overall adverse events associated with the use of parecoxib compared to placebo when used in conjunction with opioids.
Pri uporabi parekoksiba v primerjavi s placebom niso zasledili podatkov, ki bi ob sočasnem jemanju opioidov nakazovali povezavo z manjšo prisotnostjo celotnih neželenih učinkov.
There are no data on co-administration of Pumarix with other vaccines.
Podatkov o sočasni uporabi cepiva Pumarix z drugimi cepivi ni.
There are no data on fertility available.
Podatkov o plodnosti ni na voljo.
There are no data on human fertility.
Podatkov o vplivu na plodnost pri ljudeh ni.
There are no data on long term effects on sexual maturation.
Podatkov o dolgotrajnih učinkih na spolno dozorevanje ni na voljo.
There are no data on maintenance of effect or long term safety (see sections 4.4 and 4.8).
Nadzorovanih podatkov o vzdrževalnem učinku ali podatkov o dolgoročni varnosti ni (glejte poglavji 4.4 in 4.8).
There are no data on nitisinone affecting fertility.
Podatkov o vplivu nitizinona na plodnost ni.
There are no data on recurrence and progression rates beyond 1 year.
Ni podatkov glede stopnje ponovitve in napredovanja za čas po enem letu.
There are no data on the clinical safety and efficacy of multiple doses of abiraterone acetate when administered to patients with moderate or severe hepatic impairment (Child-Pugh Class B or C).
Podatkov o klinični varnosti in učinkovitosti večkratnih odmerkov abirateronacetata pri bolnikih z zmerno do hudo okvaro jeter (Child-Pugh razred B ali C) ni.
There are no data on the effect of ferric maltol on human fertility.
Podatkov o učinku izpostavljenosti železovemu maltolu na plodnost pri človeku ni.
There are no data on the effect of JETREA on fertility.
Podatkov o vplivu zdravila JETREA na plodnost ni.
There are no data on the effect of NEVANAC on human fertility.
Podatkov o vplivu zdravila NEVANAC na sposobnost razmnoževanja pri ljudeh ni.
There are no data on the effect of olaratumab on human fertility.
Podatkov o vplivu olaratumaba na plodnost pri človeku ni.
There are no data on the effect of TRISENOX on the QTc interval during the infusion.
Podatkov o učinku zdravila TRISENOX na interval Q-Tc med infundiranjem ni.
There are no data on the effects of amifampridine on the metabolism or active secretion of other medicinal products.
Ni podatkov o učinkih amifampridina na presnovo ali aktivno izločanje drugih zdravil.
There are no data on the effects of bimatoprost on human fertility.
Ni podatkov o učinkih bimatoprosta na plodnost pri ljudeh.
There are no data on the effects of GANFORT on human fertility.
Podatkov o učinkih zdravila GANFORT na plodnost pri človeku ni.
There are no data on the effects of GANFORT single-dose on human fertility.
Podatkov o učinkih zdravila GANFORT (enoodmerna oblika) na plodnost pri človeku ni.
There are no data on the effects of Ruconest on male or female fertility.
O učinkih zdravila Ruconest na moško ali žensko plodnost ni podatkov.
There are no data on the effects of Tecfidera on human fertility.
Ni podatkov o vplivu zdravila Tecfidera na plodnost pri ljudeh.
There are no data on the impact of ONIVYDE on human fertility.
Ni podatkov o vplivu zdravila ONIVYDE na plodnost pri človeku.
There are no data on the interchangeability of 100 mg or 50 mg Viramune prolonged-release tablets compared to 400 mg prolonged-release tablets and therefore, neither 50 mg nor 100 mg prolonged- release tablets should be taken by adults.
O zamenljivosti zdravila Viramune 100 mg tablete s podaljšanim sproščanjem ali 50 mg tablete s podaljšanim sproščanjem v primerjavi s 400 mg tabletami s podaljšanim sproščanjem ni podatkov, zato odrasli ne smejo jemati 50 mg ali 100 mg tablet s podaljšanim sproščanjem.
There are no data on the pharmacokinetics, safety or efficacy of clofarabine in infants.
Podatkov o farmakokinetiki, varnosti in učinkovitosti klofarabina pri dojenčkih ni.
There are no data on the safety and efficacy in patients under the age of 18 years.
Podatkov o varnosti in učinkovitosti pri bolnikih pod 18 let ni.
There are no data on the safety of MabThera in patients with moderate heart failure (NYHA class III) or severe, uncontrolled cardiovascular disease.
Podatkov o varnosti zdravila MabThera pri bolnikih z zmernim srčnim popuščanjem (III. razred NYHA) ali hudo, neobvladljivo boleznijo srca ni.
There are no data on the use of avanafil during breast-feeding.
Podatkov o uporabi avanafila med dojenjem ni.
There are no data on the use of Bondenza in these age groups.
O uporabi zdravila Bondenza pri tej skupini bolnikov ni podatkov.
There are no data on the use of Bondronat in patients less than 18 years old.
O uporabi zdravila Bondronat pri bolnikih, mlajših od 18 let, ni podatkov.
There are no data on the use of Bondronat in patients less than 18 years old.
O uporabi zdravila Bondronat pri bolnikih, mlajših od 18 let, ni zadostnih podatkov.
There are no data on the use of Bonviva in these age groups.
O uporabi zdravila Bonviva pri tej skupini bolnikov ni podatkov.
There are no data on the use of ceftolozane/tazobactam in pregnant women.
Podatkov o uporabi ceftolozana/tazobaktama pri nosečnicah ni.
There are no data on the use of Epclusa in patients with HCV/HBV co-infection.
Podatkov o uporabi zdravila Epclusa pri bolnikih s sočasno okužbo z virusoma HCV in HBV ni.
There are no data on the use of Iasibon in patients less than 18 years old.
O uporabi zdravila Iasibon pri bolnikih, mlajših od 18 let, ni podatkov.
There are no data on the use of Iasibon in patients less than 18 years old.
O uporabi zdravila Iasibon pri bolnikih, mlajših od 18 let, ni zadostnih podatkov.
There are no data on the use of ibandronic acid in patients less than 18 years old.
O uporabi ibandronske kisline pri bolnikih, mlajših od 18 let, ni podatkov.
There are no data on the use of ibandronic acid in patients less than 18 years old.
O uporabi ibandronske kisline pri bolnikih, mlajših od 18 let, ni zadostnih podatkov.
There are no data on the use of ibandronic acid in these age groups.
O uporabi ibandronske kisline pri tej skupini bolnikov ni podatkov.
There are no data on the use of Ibandronic acid Sandoz in patients less than 18 years old.
O uporabi zdravila Ibandronska kislina Sandoz pri bolnikih, mlajših od 18 let, ni podatkov.
There are no data on the use of INCIVO in patients with HCV/HBV co-infection.
Ni podatkov o uporabi zdravila INCIVO pri bolnikih, ki imajo sočasno okužbo s HCV in HBV.
There are no data on the use of Kivexa in pregnancy, however the malformative risk is unlikely in humans based on those data.
Na podlagi teh podatkov ni verjetno, da bi bilo zdravilo Kivexa pri človeku povezano s tveganjem za malformacije, kljub temu, da ni podatkov o uporabi zdravila Kivexa med nosečnostjo.
There are no data on the use of LITAK in patients with renal or hepatic impairment.
O uporabi zdravila LITAK pri bolnikih z okvarjenim delovanjem ledvic ali jeter ni podatkov.
There are no data on the use of MACI during breast-feeding.
Podatkov o uporabi zdravila MACI med dojenjem ni.
There are no data on the use of macitentan in pregnant women.
Podatkov o uporabi macitentana pri nosečnicah ni.
There are no data on the use of pembrolizumab in pregnant women.
Podatkov o uporabi pembrolizumaba pri nosečnicah ni.
There are no data on the use of Sovaldi in patients with HCV/HBV co-infection.
Podatkov o uporabi zdravila Sovaldi pri bolnikih s sočasno okužbo z virusoma HCV in HBV ni.
There are no data on the use of this medicinal product in pregnant women.
Podatkov o uporabi tega zdravila pri nosečnicah ni.
There are no data on the use of Triumeq in pregnancy.
O uporabi zdravila Triumeq med nosečnostjo ni podatkov.
There are no data on the use of vandetanib in breast-feeding women.
Podatkov o uporabi vandetaniba pri doječih ženskah ni.
There are no data on the use of Victrelis in pregnant women.
Podatkov o uporabi zdravila Victrelis pri nosečnicah ni.
There are no data on the use of Xofigo in patients with Crohn’s disease (a long-term inflammatory disease of the intestines) and with ulcerative colitis (a long-term inflammation of the colon).
Podatkov o uporabi zdravila Xofigo pri bolnikih s Crohnovo boleznijo (dolgotrajna vnetna črevesna bolezen) in z ulceroznim kolitisom (dolgotrajno vnetje debelega črevesa) ni.
There are no data on the use of Zalmoxis during breast-feeding.
Podatkov o uporabi zdravila Zalmoxis med dojenjem ni.
There are no data on the use of ZOSTAVAX in pregnant women.
Podatkov o uporabi cepiva ZOSTAVAX pri nosečnicah ni.
There are no data on treatment with SIRTURO longer than 24 weeks within the clinical studies C208 and C209 (see section 5.1).
V kliničnih študijah C208 in C209 ni podatkov o zdravljenju z zdravilom SIRTURO, ki bi trajalo več kot 24 tednov (glejte poglavje 5.1).
There are no data on which to base a dose recommendation in patients weighing
Ni podatkov, na katerih bi temeljila priporočila o odmerku pri bolnikih s telesno maso
There are no data regarding necitumumab administration in patients with moderate or severe hepatic impairment (see section 5.2).
Ni podatkov o dajanju necitumumaba bolnikom z zmerno ali hudo okvaro jeter (glejte poglavje 5.2).
There are no data regarding the effect of rasburicase on fertility.
Podatkov o učinku razburikaze na plodnost ni.
There are no data regarding the effects of withdrawal of concomitant anti-epileptic medicinal products to achieve monotherapy with perampanel.
Podatkov o učinkih prenehanja sočasne uporabe antiepileptičnih zdravil za doseganje monoterapije s perampanelom ni.
There are no data regarding the effects of withdrawal of concomitant anti-epileptic medicinal products to achieve monotherapy with perampanel.
Podatkov o učinku prenehanja sočasne uporabe antiepileptičnih zdravil za doseganje monoterapije s perampanelom ni.
There are no data regarding the efficacy and only very limited data regarding the safety of emtricitabine in infants below 4 months of age.
Ni podatkov glede učinkovitosti emtricitabina pri dojenčkih, mlajših od 4-ih mesecev, podatki glede varnosti emtricitabina pa so zelo omejeni.
There are no data regarding the excretion of mepolizumab in human milk.
Podatkov o izločanju mepolizumaba v materino mleko pri človeku ni.
There are no data regarding the use of anidulafungin in pregnant women.
O uporabi anidulafungina pri nosečnicah ni podatkov.
There are no data regarding the use of axitinib in pregnant women.
Podatkov o uporabi aksitiniba pri nosečnicah ni.
There are no data regarding the use of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics during breast-feeding.
Podatkov o uporabi cepiva Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics med dojenjem ni.
There are no data related to brain-to-blood exposure ratio in humans.
Podatkov o tovrstnem razmerju pri ljudeh ni na voljo.
There are no data to guide co-administration of ISENTRESS with rifampicin in patients below 18 years of age (see section 4.4).
Na voljo ni nobenih podatkov za navodila pri sočasni uporabi zdravila ISENTRESS z rifampicinom pri bolnikih, mlajših od 18 let (glejte poglavje 4.4).
There are no data to guide co-administration of ISENTRESS with rifampicin in patients below 18 years of age (see section 4.5).
Na voljo ni nobenih podatkov za navodila pri sočasni uporabi zdravila ISENTRESS z rifampicinom pri bolnikih, mlajših od 18 let (glejte poglavje 4.5).
There are no data to support the co-administration of OLYSIO and telaprevir or boceprevir.
Podatkov, ki bi podprli sočasno uporabo zdravila OLYSIO s telaprevirjem ali boceprevirjem, ni.
There are no data to support the use of Onduarp in unstable angina pectoris and during or within one month of a myocardial infarction.
Ni podatkov, na podlagi katerih bi lahko zdravilo Onduarp uporabili pri nestabilni angini pektoris in med miokardnim infarktom ali v obdobju enega meseca po njem.
There are no data to support the use of telmisartan/amlodipine in unstable angina pectoris and during or within one month of a myocardial infarction.
Ni podatkov, na podlagi katerih bi lahko telmisartan/amlodipin uporabili pri nestabilni angini pektoris in med miokardnim infarktom ali v obdobju enega meseca po njem.
There are no data with PANDEMIC INFLUENZA VACCINE H5N1 BAXTER using the subcutaneous route.
Ni podatkov o subkutanem injiciranju cepiva PANDEMIC INFLUENZA VACCINE H5N1 BAXTER.
There are no data with Pandemic influenza vaccine H5N1 MedImmune in children and adolescents younger than 18 years of age receiving salicylate therapy.
O Cepivu proti pandemski gripi H5N1 MedImmune ni podatkov pri otrocih in mladostnikih, mlajših od 18 let, ki prejemajo zdravljenje s salicilati.
There are no data with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics using the subcutaneous route.
Podatkov o subkutani uporabi cepiva Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics ni.
There are no data with regard to overdose.
Podatkov o prevelikem odmerjanju ni.
There are no data with regard to symptomatic overdose with INTELENCE, but it is possible that the most frequent ADRs of INTELENCE, i.e. rash, diarrhoea, nausea, and headache would be the most common symptoms noted.
Ni podatkov o simptomih prevelikega odmerjanja zdravila INTELENCE; najverjetneje bi se najpogostejši neželeni učinki zdravila INTELENCE (izpuščaj, driska in glavobol) pojavili tudi kot najpogostejši simptomi prevelikega odmerjanja.
There are no data with VEPACEL using the subcutaneous route.
Ni podatkov o subkutanem injiciranju cepiva VEPACEL.
There are no dose modifications recommended for severe lymphopenia given the mechanism of action of MabCampath.
Za resno limfopenijo zaradi mehanizma delovanja zdravila MabCampath ni priporočljivih sprememb odmerkov.
There are no dosing recommendations for Baraclude in children less than 2 years of age or weighing less than 10 kg.
Priporočila za uporabo zdravila Baraclude pri otrocih, mlajših od 2 let, ali otrocih s telesno maso, manjšo od 10 kg, niso na voljo.
There are no fertility data available.
Ni podatkov o učinkih na plodnost.
There are no fertility data available.
Podatki o plodnosti niso na voljo.
There are no fertility data available.
Podatkov o plodnosti ni na voljo.
There are no fertility data in humans.
Podatkov o vplivu na plodnost pri ljudeh ni.
There are no fertility data with Clopidogrel/Acetylsalicylic acid Zentiva.
Podatkov o plodnosti za Klopidogrel/acetilsalicilna kislina Zentiva ni.
There are no fertility data with DuoPlavin.
Podatkov o plodnosti za DuoPlavin ni.
There are no fixed rules for insulin dose regimen.
Trdnih pravil za shemo odmerjanja insulina ni.
There are no human data available to support or rebut these possibilities.‌‌
Podatkov pri ljudeh, ki bi podprli ali ovrgli te možnosti, ni na voljo.
There are no human data on the use of ZYTIGA in pregnancy and this medicinal product is not for use in women of childbearing potential.
Podatkov o uporabi zdravila ZYTIGA med nosečnostjo pri ljudeh ni in zdravilo ZYTIGA ni namenjeno uporabi pri ženskah v rodni dobi.
There are no human fertility data for darifenacin.
Podatkov o vplivu darifenacina na plodnost pri ljudeh ni.
There are no indications either from this study or from post marketing adverse reaction reports that the overall safety profile in CAPS patients is different from that in RA patients.
Ni nobenih indikacij, ne iz te študije ne iz poročil o neželenih učinkih po začetku trženja, da je celotni varnostni profil bolnikov s CAPS drugačen od bolnikov z RA.
There are no interaction data available on the coadministration of indinavir/ritonavir and amprenavir.
Podatkov o medsebojnem delovanju pri
There are no known conditions in which you must not be given Xofigo.
Ni znanih zdravstvenih stanj, zaradi katerih ne bi smeli prejeti zdravila Xofigo.
There are no known contraindications to the use of Xofigo.
Ni znanih kontraindikacij za uporabo zdravila Xofigo.
There are no known incompatibilities with other medicinal products.
Znanih inkompatibilnosti z drugimi zdravili ni.
There are no known interactions of Desloratadine Actavis with other medicines.
Ni znanih interakcij med zdravilom Desloratadin Actavis in drugimi zdravili.
There are no known interactions of Desloratadine ratiopharm with other medicines.
Ni znanih interakcij med zdravilom Desloratadin ratiopharm in drugimi zdravili.
There are no known side effects of having too much SYLVANT.
Neželeni učinki zaradi prejema prevelike količine zdravila SYLVANT niso znani.
There are no known side effects on the unborn or new- born baby.
Pri plodu ali novorojenčku ni znanih neželenih učinkov.
There are no known side effects with Evalon.
Znanih neželenih učinkov zdravila Evalon ni.
There are no known side effects with Vectormune ND.
Znanih neželenih učinkov cepiva Vectormune ND ni.
There are no known side effects.
Znanih neželenih učinkov ni.
There are no long-term data on the effect of fulvestrant on bone.
Dolgoročnih podatkov o učinku fulvestranta na kosti ni na voljo.
There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of rilpivirine in pregnant women.
Na voljo je le malo podatkov o uporabi rilpivirina pri nosečnicah (manj kot 300 izidov nosečnosti).
There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of rilpivirine in pregnant women.
Podatkov o uporabi rilpivirina pri nosečnicah ni ali so omejeni (manj kot 300 izidov nosečnosti).
There are no or limited amount of data for the use of mecasermin in pregnant women.
Podatkov o uporabi mekazermina pri nosečnicah ni oziroma so omejeni.
There are no or limited amount of data from the use of dolutegravir in pregnant women.
Podatki o uporabi dolutegravirja pri nosečnicah so omejeni ali pa jih sploh ni.
There are no or limited amount of data from the use of sirolimus in pregnant women.
Podatkov o uporabi sirolimusa pri nosečnicah ni ali pa so omejeni.
There are no or limited amounts of data from the use of afamelanotide in pregnant women.
Podatkov o uporabi afamelanotida pri nosečnicah ni ali pa so omejeni.
There are no or limited clinical data with Stribild in pregnant women.
Kliničnih podatkov o uporabi zdravila Stribild pri nosečnicah ni oziroma so omejeni.
There are no or limited data (less than 300 pregnancy outcomes) from the use of tenofovir alafenamide in pregnant women.
Podatkov o uporabi alafenamidtenofovirata pri nosečnicah ni oziroma so omejeni (manj kot 300 izidov nosečnosti).
There are no or limited data from the use of ceftaroline fosamil in pregnant women.
Podatkov o uporabi fosamilceftarolina pri nosečnicah ni ali jih je malo.
There are no or limited data from the use of para-aminosalicylic acid in pregnant women.
Podatki o uporabi para-aminosalicilne kisline pri nosečnicah niso na voljo ali pa so omejeni.
There are no other ingredients.
Drugih sestavin zdravilo ne vsebuje.
There are no other ingredients.
Zdravilo ne vsebuje drugih sestavin.
There are no pharmacokinetic data in children.
Farmakokinetičnih podatkov pri otrocih ni.
There are no pharmacokinetic data on tenofovir alafenamide in patients with estimated CrCl < 15 mL/min.
Farmakokinetičnih podatkov o alafenamidtenofoviratu pri bolnikih z ocenjenim CrCl < 15 ml/min ni.
There are no phototoxicity concerns withartenimol, as it does not absorb in the range of 290-700 nm.
Ni pomislekov glede fototoksičnosti, povezane z artenimolom, saj se v razponu 290–700 nm ne absorbira.
There are no PK data on the use of eltrombopag in patients ≥ 75 years.
Farmakokinetičnih podatkov o uporabi eltrombopaga pri bolnikih starih 75 let in več, ni na voljo.
There are no post-marketing surveillance data available for VEPACEL.
Za cepivo VEPACEL ni na voljo podatkov o spremljanju po pridobitvi dovoljenja za promet.
There are no reports of acute overdose with Ferriprox.
Ni poročil o akutnem prevelikem odmerjanju zdravila Ferriprox.
There are no reports of transmission of the more attenuated Enders’ Edmonston strain of measles virus or the Jeryl Lynn™ strain of mumps virus from vaccine recipients to susceptible contacts.
Ni poročil o prenosu bolj oslabljenega seva Enders' Edmonston virusa ošpic ali seva Jeryl Lynn™ virusa mumpsa s cepljenih oseb na kontaktne osebe, dovzetne za okužbo z virusom ošpic in mumpsa.
There are no reports of transmission of the more attenuated Enders’ Edmonston strain of measles virus or the Jeryl Lynn™ strain of mumps virus from vaccinees to susceptible contacts.
Ni poročil o prenosu bolj oslabljenega virusa ošpic seva Enders' Edmonston ali virusa mumpsa seva Jeryl Lynn™ s cepljenih posameznikov na kontaktne osebe, dovzetne za okužbo z virusom ošpic ali mumpsa.
There are no reports of virus infections with albumin manufactured to European Pharmacopoeia specifications by established processes.
Trenutno v specifikacijah Evropske farmakopeje ni poročil o prenosu virusov preko albumina, pridobljenega z uveljavljenimi postopki.
There are no reports of virus transmissions with albumin manufactured to European Pharmacopoeia specifications by established processes.
Trenutno v specifikacijah Evropske farmakopeje ni poročil o prenosu virusov preko albumina, izdelanega z uveljavljenimi postopki.
There are no restrictions on taking Viramune with food and drink.
Za jemanje zdravila Viramune s hrano in pijačo ni nobenih omejitev.
There are no restrictions on the infant’s consumption of food or liquid, either before or after vaccination.
Glede uživanja hrane ali tekočine pred ali po aplikaciji cepiva ni omejitev.
There are no restrictions on treatment of diabetes with insulin during pregnancy, as insulin does not pass the placental barrier.
Omejitev za zdravljenje diabetesa z insulinom med nosecnostjo ni, ker insulin ne prehaja placentne pregrade.
There are no restrictions on treatment with NovoMix 30 during breast-feeding.
Omejitev za zdravljenje z zdravilom NovoMix 30 med dojenjem ni.
There are no restrictions on treatment with NovoMix 50 during breast-feeding.
Omejitev za zdravljenje z zdravilom NovoMix 50 med dojenjem ni.
There are no restrictions on treatment with NovoMix 70 during breast-feeding.
Omejitev za zdravljenje z zdravilom NovoMix 70 med dojenjem ni.
There are no restrictions on treatment with NovoRapid during breast-feeding.
Omejitev za zdravljenje z zdravilom NovoRapid med dojenjem ni.
There are no restrictions on your child’s consumption of food or liquids, either before or after vaccination.
Otrok lahko pred in po cepljenju brez omejitev uživa tako hrano kot tekočine.
There are no restrictions on your food or drink while you are receiving TRISENOX.
Med jemanjem zdravila TRISENOX ni omejitev pri hrani in pijači.
There are no safety and immunogenicity data available from clinical studies with Pandemrix (H1N1)v in children aged less than 6 months.
Iz kliničnih študij cepiva Pandemrix (H1N1)v ni podatkov o varnosti in imunogenosti pri otrocih, starih manj kot 6 mesecev.
There are no safety data available concerning use of Perjeta with doxorubicin.
Podatkov o varnosti o uporabi doksorubicina in zdravila Perjeta ni.
There are no safety data available on the use of Modigraf granules following a temporary switch from Prograf or Advagraf in critically ill patients.
Pri kritično bolnih o uporabi zrnc Modigraf po začasni zamenjavi z zdravilom Prograf ali zdravilom Advagraf, podatki o varnosti niso na voljo.
There are no side effects caused by stopping treatment with capecitabine.
Po prenehanju zdravljenja s kapecitabinom se ne pojavijo neželeni učinki.
There are no side effects when you stop Tamiflu.
Če prenehate z jemanjem zdravila Tamiflu, ne pride do pojava neželenih učinkov.
There are no side-effects caused by stopping treatment with Capecitabine SUN.
Po prenehanju zdravljenja z zdravilom Kapecitabin SUN se ne pojavijo neželeni učinki.